Compare RBC & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RBC | RPRX |
|---|---|---|
| Founded | 1919 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.5B | 19.4B |
| IPO Year | N/A | 2020 |
| Metric | RBC | RPRX |
|---|---|---|
| Price | $559.18 | $45.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $495.83 | $47.75 |
| AVG Volume (30 Days) | 206.9K | ★ 3.6M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | ★ 2.08% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.78 |
| Revenue | N/A | ★ $2,378,193,000.00 |
| Revenue This Year | $14.83 | $39.10 |
| Revenue Next Year | $12.08 | $5.02 |
| P/E Ratio | $64.90 | ★ $25.38 |
| Revenue Growth | N/A | ★ 5.06 |
| 52 Week Low | $297.28 | $29.66 |
| 52 Week High | $564.70 | $46.14 |
| Indicator | RBC | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 77.95 | 68.51 |
| Support Level | $545.51 | $42.50 |
| Resistance Level | $564.70 | $46.14 |
| Average True Range (ATR) | 13.95 | 0.96 |
| MACD | 0.05 | 0.06 |
| Stochastic Oscillator | 80.62 | 71.52 |
RBC Bearings Inc is an international manufacturer and marketer of engineered precision bearings, components, and essential systems for the industrial, defense, and aerospace industries. The offering includes plain bearings, roller bearings, ball bearings, and engineered products. The company has two reportable segments: Industrial, which derives maximum revenue, and Aerospace/Defense. The Aerospace/Defense segment represents the end markets for the company's engineered bearings and precision components used in commercial aerospace, defense aerospace, and sea and ground defense applications; and the Industrial segment represents the end markets for its products used in various industrial applications. Geographically, the company generates a majority of its revenue from the United States.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.